| Novartis Pharma Schweiz AG - Sandostatin LAR 30 mg Fertigspritzen, Injektionspräparat |
| 53161 | | 06 | | Sandostatin LAR 30 mg Fertigspritzen | | Injektionspräparat | | H01CB02 | | Octreotid | | 02.10.2003 | | |
|
| Composition |
| Praeparatio sicca: octreotidum 30 mg ut octreotidi acetas 33.6 mg, poly(lactidum-co-glycolidum), mannitolum, pro vitro.
Solvens: carmellosum natricum corresp. natrium 1.512 mg, mannitolum, poloxamerum 188, aqua ad iniectabile q.s. ad solutionem pro 2.0 ml. |
| Packungsbestandteile |
| Préparation injectable | | | | | | | | Principe actif | Concentr. | informations additionels |
|---|
| Octreotide | 30 mg | Praeparatio sicca |
| | BAG: Principe actif | Concentr. |
|---|
| Octreotide | 30 mg |
| | | | Agents auxilliaires |
|---|
| Mannitol | | Poly(Lactidum-Co-Glycolidum) |
| |
| Solvens | | | Préparation injectable | | | | | | | | | BAG: Principe actif | Concentr. |
|---|
| Octreotide | 30 mg |
| | | | Agents auxilliaires | Concentr. |
|---|
| Carmellose Sodique | | | Mannitol | | | Poloxamer | 188 |
| |
|
| numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 006 | 30 mg | 1265.46 | 1450.80 | A | LS | Oui |
|
